Thursday, April 15, 2021

Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice

xloma.fota.13 shared this article with you from Inoreader

journal.pone.0248903.g005&size=inline

by Byong H. Kang, Noor Momin, Kelly D. Moynihan, Murillo Silva, Yingzhong Li, Darrell J. Irvine, K. Dane Wittrup

Following curative immunotherapy of B16F10 tumors, ~60% of mice develop a strong antibody response against cell-surface tumor antigens. Their antisera confer prophylactic protection against intravenous challenge with B16F10 cells, and also cross-react with syngeneic and allogeneic tumor cell lines MC38, EL.4, 4T1, and CT26. We identified the envelope glycoprotein (env) of a murine endogenous retrovirus (ERV) as the antigen accounting for the majority of this humoral response. A systemically administered anti-env monoclonal antibody cloned from such a response protects against tumor challenge, and prophylactic vaccination against the env protein protects a majority of naive mice from tumor establishment following subcutaneous inoculation with B16F10 cells. These results suggest the potential for effective prophylactic vaccination against analogous HERV-K env expressed in numerous human cancers.
View on the web

No comments:

Post a Comment

Collaboration request

Hi there How would you like to earn a 35% commission for each sale for life by selling SEO services Every website owner requires the ...